Market Segmentation Strategies for mRNA COVID-19 Vaccines in Canada: Best Practices in Biomedical Product Development

Read full text Summarise with VIRAT
Authors: Aanchal Rautela, Anju Patel, Ishani Patel, Madhav Gohel, Vasavi Vangari, Yesha Gandhi, Pirouzi Pirouzi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The emergence of mRNA vaccine technology during the COVID-19 pandemic has fundamentally transformed vaccine development paradigms, offering unprecedented speed and adaptability in responding to emerging infectious diseases. As described by Pardi et al. (2018), mRNA vaccines represent a paradigm shift in vaccinology by utilizing cellular machinery to produce antigenic proteins. This article examines market segmentation strategies for mRNA-based COVID-19 vaccines within the Canadian healthcare context, addressing the unique challenges of maintaining vaccination coverage in a mature pandemic response environment. According to the Public Health Agency of Canada (2024), over 95 million COVID-19 vaccine doses have been administered nationally. The analysis identifies priority population segments including older adults aged 65 years and above who account for approximately 90% of COVID-19-related deaths (Statistics Canada, 2024), immunocompromised individuals requiring specialized vaccination approaches (Canadian Immunization Research Network, 2023), and healthcare workers with elevated occupational exposure risk. Our framework integrates demographic, epidemiological, behavioral, and healthcare system factors to optimize vaccine allocation and uptake strategies. Future directions emphasize the potential of mRNA platform technology for broader vaccine applications and the importance of maintaining healthcare system resilience through sustained vaccination programs. Keywords: mRNA vaccines, COVID-19, market segmentation, pandemic response, vaccine development, Canadian immunization programs, booster vaccination

Fields of Study & Subjects

Vaccine Coverage and Hesitancy SARS-CoV-2 and COVID-19 Research Pharmaceutical Economics and Policy

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
26 March 2026
Language
EN